Akrivis Technologies, LLC

About This Project

Products and services for the early detection and treatment of serious human diseases. The company’s Z–TECT™ Technology Platform provides ultrasensitive detection & accurate quantification of biomolecules present in the zeptomole range (10E–21 moles).

Value Proposition

In contrast with the current sensitivity–limited immunoassays Akrivis’ Z–TECT™’s range offers striking improvements in sensitivity. All Z–TECT™ performance benefits can apply to other immunoassays such as Western Blot, flow cytometry, immunohistochemistry, immunocytochemistry and radioimmunoassays.